NASDAQ:TGTX

Tg Therapeutics Stock Predictions

etoro logo Buy TGTX
*Your capital is at risk
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

TGTX Prediction Chart

TGTX Predictions History

Latest community submissions for TGTX.
Predictor Target Session Target Price Result Direction Accuracy Score
Jul 21, 2023 $21.34 +1.86% $20.62 X 96.51% 0
JS JS Pro
Jul 21, 2023 $21.00 +0.24% $20.62 X 98.16% 0
Skagitqg Skagitqg Merchant
Jan 13, 2023 Bullish $13.63 V 1
Aug 25, 2022 $8.00 +17.47% $7.63 V 95.15% 1
JS JS Pro
Jun 1, 2021 $35.89 +4.15% $34.46 X 95.85% 0
Fadel Matrooad Fadel Matrooad @FadelMatrooad.233710
Jun 1, 2021 $40.00 +16.08% $34.46 X 83.92% 0
JS JS Pro
Jan 27, 2021 $49.44 +6.53% $46.41 X 93.47% 1
Ronald Buller Ronald Buller @RonaldBuller.192861
Jan 27, 2021 Bullish $46.41 X 0
iHustle84 iHustle84 Pro
Oct 8, 2020 $32.90 +8.29% $30.38 X 91.71% 0
sander7100 yo bro sander7100 yo bro Pro @sander7100yobro.167552
Aug 13, 2020 $21.98 +7.85% $20.38 X 92.15% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for TGTX with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT TG THERAPEUTICS
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE